HSP Complete 50 (50 Billions)

Human Strain Probiotics (HSP) Complete 50 with postbiotics provides 12 clinically studied human strains at a potency of 50 billion colony forming units (CFU) per vegetarian capsule, with a balance of probiotics to target the small and large intestinal flora. Unlike enteric-coated or delayed-release products, the capsules are designed to target the duodenum and exert maximal gut-brain support, when taken with food. It is approved by Health Canada and obtained the Natural Product Number (80112169).
Ingredients: Lactobacillus plantarum (LP-115) 10 billion CFU, Lactococcus lactis (MJC18) 7 billion CFU, Lactobacillus acidophilus (DDS-1) 5 billion CFU, Lactobacillus paracasei (LPC-37) 5 billion CFU, Bifidobacterium bifidum (BB-06) 5 billion CFU, Bifidobacterium animalis subsp. lactis (BLC1) 5 billion CFU, Pediococcus acidilactici (UL5) 3 billion CFU, Lactobacillus acidophilus (LA-14) 2.2 billion CFU, Bifidobacterium animalis subsp. lactis (BL-04) 2 billion CFU, Lactococcus lactis (LL-23) 2 billion CFU, Lactobacillus rhamnosus (GG) 2 billion CFU, Bifidobacterium animalis subsp. lactis (HN019) 1.8 billion CFU.
Other Ingredients: Microcrystalline cellulose, Oryza sativa (rice) hull powder, trehalose, hypromellose, water.

The Power of Postbiotics: Postbiotics are active metabolites produced by commensal gut bacteria. HSP Complete 50 Probiotics with Postbiotics contain 3 unique strains capable of producing postbiotics. Bacteriocins are among the many compounds produced by probiotic organisms, and they help to keep the gastrointestinal environment stable and diverse.
Pediococcus acidilactici UL5 is a robust organism capable of withstanding both the human gastric and small intestinal environments. What makes this organism unique is its ability to produce a postbiotic bacteriocin called pediocin PA-1. This postbiotic bacteriocin is an active antimicrobial against pathogenic Listeria species and does not exert detrimental effects on the ileal environment, as demonstrated in a gastrointestinal model.
Similar to Pediococcus acidilactici UL5, Lactococcus lactis MJC18 is another probiotic organism capable of producing a potent postbiotic. The bacteriocin Nisin Z, a postbiotic of Lactococcus lactis MJC18, has antimicrobial activity against many gram-positive organisms such as Listeria sp., Staphylococcus sp., Bacillus, and Clostridium. Nisin Z is known for both its bactericidal and bacteriostatic actions against pathogens. When used in combination with methicillin, Nisin Z was shown to improve the efficacy of the antibiotic against methicillin-resistant Staphylococcus aureus when used topically for 3 hours on porcine skin. More recent studies have discovered that Nisin Z also exerts antiviral properties, especially in combination with antivirals.
Bifidobacterium animalis subsp. lactis BLC1 is an organism used in functional foods and supplements for over a decade. BLC1 has demonstrated some anti-cancer properties in vitro when combined with pro-anthocyanidins in a simulated gastrointestinal model.
Digestive Benefits: HSP Complete 50 is formulated with Lactobacillus acidophilus DDS-1, a strain clinically shown to reduce gastrointestinal discomfort in travel and lactose intolerance. Additionally, this strain has demonstrated an ability to regulate bowel habits and stool consistency. In a double-blind, placebo-controlled RCT, Bifidobacterium animalis subsp. lactis HN019 was shown to significantly increase frequency of bowel movements in patients with less than 3 per week.
Immune System Benefits: In another trial with adults 70 years of age and older, HN019 was shown to increase helper T lymphocytes and natural kill cell activity in patients with low immune response.
In a clinical trial comparing the effectiveness of various probiotic strains on immune responses, groups administered Lactobacillus acidophilus LA-14 or Bifidobacterium animalis subsp. lactis BL-04 were shown to significantly increase serum IgG, compared to controls. In a randomized, double-blind placebo-controlled trial, Bifidobacterium animalis subsp. lactis BL-04 was shown to reduce the incidence of respiratory tract infection and viral shedding after being administered during a rhinovirus infection and supplementing with the probiotic strain for an additional 28 days. In another double-blind placebo-controlled trial with 465 healthy adults, Bifidobacterium animalis subsp. lactis BL-04 (at a dose of 2 billion CFU) was shown to be more effective than placebo and a multi-strain probiotic (19% reduction vs. 27% reduction) in reducing the incidence of respiratory tract infection and improving immunity.
Metabolic Benefits: Chronic medical conditions like obesity and hypertension are modifiable cardiometabolic risk factors highly predictive of hospitalization. HSP probiotics have been formulated to address the inflammatory biomarkers, hypercholesterolemia, and elevated BMI typically seen in people with reduced immune function.
In a randomized double-blind placebo-controlled trial with 32 overweight and obese women, HSP strains were shown to be significantly correlated with healthy BMI, weight, fat mass, lean mass, conicity index, protein intake, monounsaturated fat intake, glycated hemoglobin, TNF-α, and IL6/IL10. The bifidobacteria HSP strains have also demonstrated specific cholesterol absorption properties, leading to decreases in serum total cholesterol and LDL-C.
Heavily Clinically Researched Strains: Lactobacillus rhamnosus GG is among the world's most heavily studied probiotic strains, and it is an integral part of the HSP Complete formula. With a dose of 2 billion CFU, the digestive, cognitive, and immune health are covered. Supplementation of rhamnosus GG has been clinically shown to reduce the risk of upper respiratory tract infections, rhinovirus-induced symptoms, acute otitis media, and antibiotic use in populations dealing with viral respiratory infections.

Recommended Usage: Assist in overall gut digestive health.
Improve intestinal transit time.
Enhance immune reactions.
Increase absorption of vitamins and nutrients.
Boost metabolism.
Stabilize gut flora during antibiotic therapy.
3 unique strains to produce postbiotics (UL5, MJC18 & BLC1) help to keep the gastrointestinal environment stable and diverse by promoting a balanced and appropriate immune response, by supporting reduction of inflammation in the gut and the body, and by having positive effects on glucose metabolism and insulin sensitivity.

Recommended Dose: Adults (18 and older): Take 1 capsule once daily or as directed by a healthcare practitioner. Take at least 2-3 hours before or after antibiotics.

Shelf stable. Store in room temperature.

Supplements & Adjuvant Therapy

A07FA51 - lactic acid producing organisms, combinations ; Belongs to the class of antidiarrheal microorganisms. Used in the treatment of diarrhea.